Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs NovoCare Pharmacy

GoodRx
Graded #116

Higher grade

vs+14.399999999999991
NovoCare Pharmacy
Graded #442

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 55.2/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +56
80
24
Dose & formulationGoodRx +4
70
66
Clinical oversightNovoCare Pharmacy +5
69
74
Labs & monitoringEven
51
51
FulfillmentGoodRx +5
81
76
Contract termsEven
55
55
GoodRx · left barNovoCare Pharmacy · right bar

The numbers

MetricGoodRxNovoCare Pharmacy
WeighScore69.6/10055.2/100
GradeCC
Scorecard rank#116#442
SemaglutideNot disclosed$349/mo (2.4 mg dose, brand-name)
Tirzepatide$299/mo (brand Zepbound)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
NovoCare Pharmacy

Graded #442 · C

Strengths

  • First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
  • $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
  • $349/mo standard self-pay is well below the ~$1,300/mo retail list price
  • Ships to all 50 states with no telehealth-platform middleman fees
  • Cold-chain logistics handled directly by Novo Nordisk

Where it loses points

  • Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
  • Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
  • No clinical support included — your own prescriber handles titration and side effects
  • Manufacturer-set pricing can change at any time
  • $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard